ArticleActa Cardiologica Sinica2021
Pentraxin 3 as a Marker for Cardiovascular Disease Risk in Overweight and Obese Children.
Article in Acta Cardiologica Sinica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 8 citations in OpenAlex.
- [Research progress on the diagnosis of pediatric heart failure].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Review
- Evaluation of Pentraxin 3 and Serum Amyloid A in the Gingival Crevicular Fluid of Patients with Periodontal Disease and Obesity.Journal of clinical medicine · 2023Article
- Potential Predictive Value of Serum Pentraxin 3 and Paraoxonase 1 for Cardiometabolic Disorders Development in Patients with Psoriasis-Preliminary Data.Metabolites · 2022Article
- Pentraxin 3: A Biomarker Link between Inflammation and Cardiovascular Risk among Obese Children.Acta Cardiologica Sinica · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPentraxin 3 is an inflammatory mediator that may be associated with subclinical inflammation in atherosclerosis and cardiovascular diseases. This study investigated the predictive value of pentraxin 3 as an inflammatory biomarker in overweight and obese children.
methodsParticipants were categorized into three groups: overweight (n = 35), obese (n = 35), and healthy controls (n = 70). Cardiovascular parameters and pentraxin 3 were measured in all participants.
resultsThe mean pentraxin 3 level was significantly higher in the overweight (10.23 ± 4.42 ng/ml) and obese (11.20 ± 4.12 ng/ml) groups compared to the control (7.93 ± 4.35 ng/ml) group. Pentraxin 3 was significantly correlated with carotid intima media thickness and epicardial adipose tissue thickness in the overweight group. In the linear regression analysis, body mass index and systolic blood pressure were significantly correlated with pentraxin 3 levels in the overweight group, whereas only heart rate was correlated with pentraxin 3 levels in the obese group. In receiver operating characteristic analysis, the optimal cut-off value for pentraxin 3 in the obese group was 9.321 ng/mL, with sensitivity and specificity of 77.1% and 74.3%, respectively [area under the curve (AUC) = 0.764, p < 0.001]. In the overweight group, the optimal cut-off value of pentraxin 3 was 9.263 ng/mL, with sensitivity and specificity of 62.9% and 72.9%, respectively (AUC = 0.687, p = 0.002).
conclusionsPentraxin 3 may be an early marker of cardiovascular risk in overweight children. Future longitudinal studies are needed to evaluate the predictive value of pentraxin 3 for cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.